Floxabactin vet. (30 kg)

10 x 10 pc

Tablet

Active substance

Enrofloxacin : 150 mg

ATC code

QJ01MA90 Enrofloxacin

QJ01MA Fluoroquinolones

QJ01M Quinolone and quinoxaline antibacterials

QJ01 Antibacterials for systemic use

QJ Antiinfectives for systemic use

Species

Dogs

Indications

Treatment of lower urinary tract infections (associated or not with prostatitis) and upper urinary tract infections caused by Escherichia coli or Proteus mirabilis.

Treatment of superficial and deep pyoderma.

Dose to be administered and administration route

Oral use

5 mg of enrofloxacin/kg/day as a single daily dosing, i.e. one tablet for 30 kg daily for:

- 10 days in lower urinary tract infections

- 15 days in upper urinary tract infections and lower urinary tract infections associated with prostatitis

- Up to 21 days in superficial pyoderma depending on clinical response

- Up to 49 days in deep pyoderma depending on clinical response

The treatment should be considered in case of lack of clinical improvement at half of the treatment duration.

The tablets may be administered directly in the mouth of the dog or simultaneously with food if necessary.

Do not exceed the recommended treatment dose.

After breaking a tablet, use the remaining tablet half for the next dose. Store the tablet half in the original blister pocket.

Adverse reactions

Dogs:

Rare

(1 to 10 animals / 10,000 animals treated):

Vomiting Anorexia

Undetermined frequency (cannot be estimated from the available data):

Hypersensitivity reaction

Central nervous system disorder

Joint cartilage disorder ^a

^a Possible joint cartilage alterations in growing puppies (see 3.3 ‘Contraindications’).

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.